MHRA (UK) approves donanemab to treat mild cognitive impairment and mild dementia in the UK – Eli Lilly
Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks… read more.
